# Lapatinib Resistance in Patients With Breast Cancer

> **NCT00898573** · — · WITHDRAWN · sponsor: **Case Comprehensive Cancer Center**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** lapatinib ditosylate
- **GENETIC:** fluorescence in situ hybridization
- **GENETIC:** gene expression analysis
- **GENETIC:** mutation analysis
- **GENETIC:** polymerase chain reaction
- **GENETIC:** reverse transcriptase-polymerase chain reaction
- **OTHER:** cell sorting
- **OTHER:** immunohistochemistry staining method
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00898573
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-07
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00898573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00898573, "Lapatinib Resistance in Patients With Breast Cancer". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT00898573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*